Hypertrophic Pachymeningitis in Chinese Patients: Presentation, Radiological Findings, and Clinical Course
- PMID: 32879880
- PMCID: PMC7448121
- DOI: 10.1155/2020/2926419
Hypertrophic Pachymeningitis in Chinese Patients: Presentation, Radiological Findings, and Clinical Course
Abstract
Background: Hypertrophic pachymeningitis (HP) is generally regarded as a rare inflammatory disease, which results in a diffuse thickening of the dura mater. We retrospectively collected data from patients with HP.
Methods: A total of 16 patients with HP were included in our study. The clinical features, laboratory evaluation, imaging findings, treatment, and outcome were reviewed.
Results: Of the 16 cases, half were male, with a mean age of 52.6 ± 13.2 years. The mean duration from onset to diagnosis was 8.6 months. The most frequent presenting symptoms in HP cases were a recurrently chronic headache (81.3%) and multiple cranial nerve injury (50%). Antineutrophil cytoplasmic antibody- (ANCA-) related HP was found in 5 cases and IgG4-related HP in 1 case. The intracranial pressure was elevated in 4 cases. The cerebrospinal fluid (CSF) had lymphocytosis in 5 cases and increased protein in 12 cases. Immunoglobulins (IgG, IgA, and IgM) and protein showed linear relationships in the CSF. On magnetic resonance imaging (MRI), localized or diffuse dura maters were thickened in all cases. HP combined with subacute subdural hemorrhage or hypertrophic spinal pachymeningitis was also observed in individual cases. Biopsy of the dura mater in one case showed amounts of inflammatory cells infiltrating, with an increased percentage of IgG4-positive plasma cells. Of all cases referring to glucocorticoid treatment, the symptoms have improved significantly in 10 cases. In other 6 cases, mycophenolate mofetil or azathioprine was added. All patients showed clinical improvement at the follow-up visits.
Conclusion: The clinical characters of HP are chronic onset, recurrently chronic headache, and multiple cranial nerves paralysis. Inflammatory changes in CSF caused by intrathecal synthesis of immunoglobulin, characteristic dural enhancement on MRI, and pathologic biopsy are all helpful for diagnosis. The addition of immunosuppressant, especially mycophenolate mofetil, is a good choice for steroid-resistance HP.
Copyright © 2020 Zhuajin Bi et al.
Conflict of interest statement
The authors declare that they have no conflicts of interest.
Figures




Similar articles
-
The clinical and imaging features of hypertrophic pachymeningitis: a clinical analysis on 22 patients.Neurol Sci. 2019 Feb;40(2):269-274. doi: 10.1007/s10072-018-3619-4. Epub 2018 Oct 30. Neurol Sci. 2019. PMID: 30377845
-
Pachymeningitis associated with IgG4-related disease and ANCA positivity: Case report and review of the literature.Autoimmun Rev. 2023 Apr;22(4):103285. doi: 10.1016/j.autrev.2023.103285. Epub 2023 Feb 2. Autoimmun Rev. 2023. PMID: 36738953 Review.
-
Distinct features of ANCA-associated hypertrophic pachymeningitis compared with other etiologies: findings from a study of 74 patients.Rheumatology (Oxford). 2025 Mar 1;64(3):1292-1301. doi: 10.1093/rheumatology/keae293. Rheumatology (Oxford). 2025. PMID: 38759113
-
Hypertrophic pachymeningitis.J Neurol Sci. 2016 Aug 15;367:278-83. doi: 10.1016/j.jns.2016.06.024. Epub 2016 Jun 11. J Neurol Sci. 2016. PMID: 27423604
-
[Inflammatory hypertrophic cranial pachymeningitis].Presse Med. 2001 Mar 10;30(9):411-6. Presse Med. 2001. PMID: 11285778 Review. French.
Cited by
-
Misleading Rare Case of Idiopathic Hypertrophic Pachymeningitis.Case Rep Med. 2024 Mar 13;2024:5561686. doi: 10.1155/2024/5561686. eCollection 2024. Case Rep Med. 2024. PMID: 38510534 Free PMC article.
-
Two cases of MPO-ANCA-positive hypertrophic pachymeningitis mimicking as intracranial infection.BMC Neurol. 2024 Aug 13;24(1):283. doi: 10.1186/s12883-024-03785-y. BMC Neurol. 2024. PMID: 39138403 Free PMC article.
-
Hypertrophic pachymeningitis in ANCA-associated vasculitis: a cross-sectional and multi-institutional study in Japan (J-CANVAS).Arthritis Res Ther. 2022 Aug 23;24(1):204. doi: 10.1186/s13075-022-02898-4. Arthritis Res Ther. 2022. PMID: 35999568 Free PMC article.
-
Hypertrophic pachymeningitis in polyarteritis nodosa: a case-based review.Clin Rheumatol. 2022 Feb;41(2):567-572. doi: 10.1007/s10067-021-05971-6. Epub 2021 Nov 2. Clin Rheumatol. 2022. PMID: 34725743 Review.
-
The Spectrum of Intracranial Hypertrophic Pachymeningitis at an Eastern Indian Tertiary Care Center.Ann Indian Acad Neurol. 2023 Sep-Oct;26(5):678-689. doi: 10.4103/aian.aian_561_23. Epub 2023 Oct 7. Ann Indian Acad Neurol. 2023. PMID: 38022439 Free PMC article.
References
-
- Prabhakar S., Bhatia R., Lal V., Singh P. Hypertrophic pachymeningitis: varied manifestations of a single disease entity. Neurology India. 2002;50(1):45–52. - PubMed
-
- Ikeda J., Shimojima Y., Usami Y., Ueno K. I., Kishida D., Sekijima Y. Cerebrospinal fluid biomarkers implicated in the pathogenesis of anti-neutrophil cytoplasmic antibody-related hypertrophic pachymeningitis. Clinical Rheumatology. 2020;39(6):1803–1811. doi: 10.1007/s10067-020-04971-2. - DOI - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous